Iron overload and HFE gene mutations in Polish patients with liver cirrhosis

Sikorska, Katarzyna; Romanowski, Tomasz; Stalke, Piotr; Iżycka‐Świeszewska, Ewa; Bielawski, Krzysztof Piotr

doi:10.1016/s1499-3872(11)60045-3

Cited by 17 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from the Jowkar et al [4] study are similar to those published from Indian and Turkish patients [5][6]. More recently, Sikorska et al [7] studied iron overload and HFE gene mutations in Polish patients with liver cirrhosis (61 patients), and they were compared with a control group of 42 consecutive patients subjected to liver biopsy because of chronic liver disease. They concluded that iron disorders are frequently detected in patients with liver cirrhosis, but without significant association with HFE gene mutations.…”

supporting

confidence: 59%

Iron Overload and HFE Mutations: Are They Relevant in Cryptogenic Cirrhosis?

Castiella

2012

Hepat Mon

View full text Add to dashboard Cite

supporting

confidence: 59%

Iron Overload and HFE Mutations: Are They Relevant in Cryptogenic Cirrhosis?

Castiella

2012

Hepat Mon

View full text Add to dashboard Cite

“…However, there are no studies that have associated the S65C mutation to extensive liver fibrosis. [22][23][24][25] Treatment of hemochromatosis consists of weekly phlebotomies, removing 400-500 ml each time until S-ferritin is about 50 µg/l. When iron stores are depleted patients continue treatment with phlebotomies 2-6 times a year.…”

Section: Hereditary Hemochromatosismentioning

confidence: 99%

Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis

Söderberg

Marmur

Eckes

et al. 2011

Apmis

View full text Add to dashboard Cite

Great progress has been made in understanding the development of non-alcoholic fatty liver disease (NAFLD) but less is known about the mechanisms underlying the progress from steatosis to steatohepatitis (NASH). Our aim was to evaluate if the amount and type of storage of fat in hepatocytes is of importance for hepatocyte injury. We also wanted to show if not only the innate immunity but also the adaptive immunity is involved in NASH. Thirty-one patients with NASH or borderline NASH and 18 non-NASH patients were investigated. Liver biopsies were scored for NASH according to Kleiner et al. Paraffin-embedded liver biopsies were stained with antibodies against CD3, TLR4, CD68, Cleaved Caspase-3, ICAM1, Foxp3 and ApopTag by immunohistochemistry. Serum soluble ICAM-1 (sICAM-1) were analysed by ELISA. The volume density of fat was 59% in the NASH patients and microvesicular fat, increased in high NAS score patients. ICAM-1 positive hepatocytes were seen in NASH patients and were localized in areas with microvesicular fat. Non-NASH biopsies were negative for ICAM-1 positive hepatocytes. The sICAM-1 were significantly higher in NASH-patients (339.8 ± 34.07) than in non-NASH patients (229.5 ± 12.14), p = 0.0015. Patients with NAS score over four had higher area of CD68 positive cells p = 0.0011 and Foxp3 positive cells (p = 0.024) than non-NASH patients. In liver tissue with NASH, hepatocytes with microvesicular steatosis seem to be expressing more inflammatory markers, and in this liver tissue an increased number of CD68 cells and regulatory T-cells (Tregs, e.g. Foxp3+ cells) were seen, indicating an involvement of, both the innate and the adaptive immunity.

show abstract

“…This possibly better viral response in children may be associated with shorter duration of HCV infection, lower frequency of liver fibrosis and iron overload, and lower rate of risky behavior (intravenous drug usage, alcohol consumption, etc.) and comorbidities (4)(5)(6). Treatment with peg-IFnα-2b and RBV is associated with several, and sometimes severe, adverse events, which may affect the treatment efficacy and the patient's adherence to the treatment regimen.…”

Section: Introductionmentioning

confidence: 99%

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

Pawłowska¹,

Pilarczyk

Foksinska

et al. 2011

Hepat Mon

View full text Add to dashboard Cite

Article type: original ArticleBackground: Treatment of hepatitis C virus (HCV) infection with interferon (IFn) and ribavirin (RBV) is associated with adverse events, which may affect the patient's adherence to the treatment regimen and the treatment efficacy. Objectives: The aim of this study was to assess the sustained viral response (SVR) and interdependence between the haematological characteristics (leukocyte count, platelet count, and haemoglobin levels) in patients with chronic hepatitis C (CHC) infection during treatment with IFn and RBV. Patients and Methods:We conducted a retrospective cohort study of 170 children with CHC infection who completed treatment with IFn-α and RBV. The children were divided into 2 groups: the first group (group I, n = 119) underwent a 48-week course of treatment with recombinant IFn α-2b (Intron A) at a dosage of 3 MU 3 times a week subcutaneously and RBV at a dosage of 15 mg/kg per day orally, and the second group (group II, n = 51) was administered pegylated IFn (peg-IFn)-α-2b (pegIntron) at a dosage of 1.5 µg/kg per week subcutaneously and RBV at a dosage of 15 mg/kg per day orally for 48 weeks. The dose of IFn was not adjusted but that of ribavirin was in 2 children from group II. Hematological growth factors and erythropoietin were not used. SVR was defined as undetectable serum HCV RnA 24 weeks after the end of treatment (study week 72). Serum HCV RnA was determined by performing polymerase chain reaction, and the HCV genotypes and hematological parameters were evaluated. Serum HCV RnA levels were analysed by descriptive statistics. Means and standard deviations were calculated for values collected at the baseline, on the 12th and 48th weeks during treatment, and after 24 weeks of untreated follow-up (study week 72). Results: eighty-six (50%) of the 170 patients who underwent treatment achieved SVR: 62 (51%) out of 119 children from group I and 24 (47%) out of 51 from group II. The mean serum hemoglobin levels and leukocyte and platelet counts at week 12 were significantly lower than the baseline values in both responders and non-responders from both the groups (P < 0.05). In the responders in group I, the mean levels of serum hemoglobin after 24 weeks of treatment and at the end of therapy were significantly lower than the mean levels at baseline. In the group treated with peg-IFn-α-2b and RBV (group II), the mean serum hemoglobin levels at week 12 was lower in the responders than in the non-responders (P < 0.05). The decrease in the hemoglobin levels was associated with viral response. In both the responders and nonresponders from both the groups, leukocyte counts decreased during treatment, and after 12 weeks, they were more significantly lower than the baseline value. The decrease was more marked in children treated with peg-IFn-α-2b + RBV (P < 0.05). After 12 weeks of treatment, the platelet count was low in children from group II who had achieved SVR. Conclusions: A mild decrease in hemoglobin levels and leukocyte and platelet counts during treatment with IFn and ...

show abstract

Iron overload and HFE gene mutations in Polish patients with liver cirrhosis

Cited by 17 publications

References 35 publications

Iron Overload and HFE Mutations: Are They Relevant in Cryptogenic Cirrhosis?

Iron Overload and HFE Mutations: Are They Relevant in Cryptogenic Cirrhosis?

Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection

Contact Info

Product

Resources

About